Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Finished Goods (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Finished Goods for 9 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 10.36% year-over-year to $6.9 million, compared with a TTM value of $6.9 million through Dec 2025, up 10.36%, and an annual FY2025 reading of $6.9 million, up 10.36% over the prior year.
  • Finished Goods was $6.9 million for Q4 2025 at Heron Therapeutics, down from $10.9 million in the prior quarter.
  • Across five years, Finished Goods topped out at $22.0 million in Q3 2022 and bottomed at $6.2 million in Q4 2024.
  • Average Finished Goods over 5 years is $11.6 million, with a median of $9.9 million recorded in 2023.
  • Peak annual rise in Finished Goods hit 319.6% in 2021, while the deepest fall reached 61.07% in 2021.
  • Year by year, Finished Goods stood at $6.3 million in 2021, then soared by 199.22% to $18.7 million in 2022, then plummeted by 47.0% to $9.9 million in 2023, then tumbled by 37.11% to $6.2 million in 2024, then increased by 10.36% to $6.9 million in 2025.
  • Business Quant data shows Finished Goods for HRTX at $6.9 million in Q4 2025, $10.9 million in Q3 2025, and $11.0 million in Q2 2025.